![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/25/2903739/0/en/BioVie-Presents-Protocol-Design-of-Upcoming-SUNRISE-PD-Phase-2-Trial-of-Bezisterim-in-Patients-with-Early-Parkinson-s-Disease-at-ATMRD-2024.html
https://www.globenewswire.com/news-release/2024/06/20/2901612/0/en/BioVie-to-Present-Protocol-Design-for-Upcoming-Phase-2-Trial-of-Bezisterim-in-Patients-with-Early-Parkinson-s-Disease-at-2024-ATMRD-Congress.html
https://www.globenewswire.com/news-release/2024/06/12/2897530/0/en/Join-BioVie-s-Exclusive-Live-Investor-Webinar-and-Q-A-Session-on-June-26.html
https://www.globenewswire.com/news-release/2024/06/04/2893004/0/en/BioVie-Announces-Formation-of-Advisory-Board-for-Bezisterim-in-Long-COVID.html
https://www.globenewswire.com/news-release/2024/05/22/2886427/0/en/BioVie-s-Bezisterim-Demonstrates-Potential-Improvements-in-Sleep-Fatigue-and-Restless-Leg-Symptoms-for-Parkinson-s-Disease-Patients.html
https://www.globenewswire.com/news-release/2024/04/29/2871172/0/en/BioVie-Awarded-up-to-13-1-Million-in-Funding-from-U-S-Department-of-Defense-to-Evaluate-Bezisterim-NE3107-for-the-Treatment-of-Long-COVID.html
https://www.globenewswire.com/news-release/2024/04/25/2869602/0/en/BioVie-Presents-Data-Showing-Potential-for-Bezisterim-NE3107-to-Reduce-Inflammation-and-Restore-Homeostasis-in-a-Manner-Correlated-with-Alzheimer-s-Disease-and-Biomarker-Endpoints.html
https://www.globenewswire.com/news-release/2024/04/18/2865316/0/en/BioVie-to-Present-Data-Showing-How-NE3107-Potentially-Restores-Homeostasis-via-Specific-Genes-Associated-with-Dementia-Metabolism-and-Inflammation.html
https://www.fiercebiotech.com/biotech/biovie-terminates-most-de-risked-program-seeks-partners-phase-3-ready-ascites-asset
https://www.globenewswire.com//news-release/2024/03/11/2843749/0/en/BioVie-Announces-Pipeline-Update-and-Near-Term-Clinical-Priorities.html